UK Dravet Syndrome Launch Readiness

Cannabidiol (Epidiolex, Jazz) and fenfluramine (Fintepla, UCB) are both NICE-commissioned (TA614 and TA808 respectively) and together define the UK Dravet standard of care: of an estimated 2,000-2,500 UK Dravet patients, 1,500-2,000 are on CBD and 400-600 are on the CBD-plus-fenfluramine combination. But combination therapy does not resolve the disease for everyone — an estimated 600-900 UK patients fail to achieve a 50% or greater seizure reduction on that combined background, concentrated at 6-8 NHS specialist paediatric epilepsy centres (GOSH, Bristol, Alder Hey, Birmingham Children's, Leeds, Newcastle). This refractory cohort, not the broader Dravet population, is the addressable NICE submission target for any new entrant, and the trial comparator must be the combined background, not monotherapy.

Fenfluramine's NICE commissioning carries a mandatory cardiac-monitoring requirement (echocardiography at initiation, 3 and 6 months, then annually), and NHS paediatric echo waiting times of 4-12 weeks mean an estimated 15-25% of NHS-eligible Dravet patients are not receiving fenfluramine due to monitoring-capacity friction rather than clinical ineligibility. A new Dravet agent without a cardiac-monitoring requirement removes both a clinical access barrier and a real NHS cost — each echocardiogram runs £200-400, and the monitoring schedule adds £800-2,400/patient/year in NHS cost that a REMS-free profile avoids outright. Soticlestat (Takeda/Ovid), with positive Phase 3 ELEKTRA data and no cardiac-monitoring requirement, is the clearest UK competitive benchmark: expected MHRA filing in 2025 and NICE technology appraisal in 2026-2027 puts it on a near-identical timeline to compete for the same refractory population.

The pre-launch sequence: engage the British Paediatric Neurology Association's Dravet working group 18-24 months ahead of NICE submission (their clinical guidance shapes NICE evidence review directly), and sponsor Dravet UK's patient survey and NICE patient group submission 12-18 months pre-filing (typical budget £20,000-40,000), specifically characterising the refractory cohort rather than the broad Dravet population. Model a WAC of £30,000-50,000/year with a 30-40% PAS to reach an effective NHS price of £18,000-35,000, within NICE's standard threshold, and build the cardiac-monitoring-free cost saving explicitly into the economic model. NICE's CG137 guideline mandates SUDEP risk counselling for uncontrolled epilepsy; include the SUDEP-reduction argument, and track soticlestat's ELEKTRA data and MHRA timeline as the defining competitive benchmark before finalising submission strategy.

This assessment synthesises three research angles into a single UK Dravet launch readiness view: competitive positioning against cannabidiol and fenfluramine, refractory-population sizing anchored in Dravet UK charity census data, and anticipated NICE/NHS payer posture derived from the TA614 and TA808 decisions.

Sources: NICE TA614 cannabidiol decision document; NICE TA808 fenfluramine decision document; Dravet UK annual report 2023; British Paediatric Neurology Association Dravet working group guidance; NHS Genomics Medicine Service SCN1A panel data; ELEKTRA ClinicalTrials.gov registration (soticlestat); NICE CG137 epilepsy SUDEP guidance.